Literature DB >> 23044390

Effect of ranolazine on ventricular repolarization in class III antiarrhythmic drug-treated rabbits.

Gerrit Frommeyer1, Dennis Kaiser, Timo Uphaus, Sven Kaese, Nani Osada, Sridharan Rajamani, Luiz Belardinelli, Günter Breithardt, Lars Eckardt, Peter Milberg.   

Abstract

BACKGROUND: Ranolazine exhibits a synergistic effect in combination with class III drugs to suppress atrial fibrillation.
OBJECTIVE: To investigate whether a combination therapy affects repolarization and provokes ventricular tachyarrhythmias (VT) in a sensitive model of proarrhythmia.
METHODS: Thirty-seven rabbits were assigned to 3 groups and fed with amiodarone (50 mg/kg/d; n = 10) or dronedarone (50 mg/kg/d; n = 10) over a period of 6 weeks. A third group was used as control (n = 17). After obtaining baseline data in Langendorff-perfused control hearts, sotalol (100 μM) was administered in this group. Thereafter, ranolazine (10 μM) was additionally infused on top of amiodarone, dronedarone, or sotalol.
RESULTS: Chronic treatment with amiodarone or dronedarone as well as sotalol significantly increased action potential duration at 90% repolarization (APD(90)). Additional treatment with ranolazine further increased APD(90) in amiodarone- and dronedarone-pretreated hearts but not in sotalol-treated hearts. Ranolazine increased postrepolarization refractoriness as compared with amiodarone or dronedarone alone owing to a marked effect on the refractory period. In contrast to amiodarone and dronedarone, acute application of sotalol increased dispersion of repolarization (P < .05). Additional treatment with ranolazine did not further increase spatial or temporal dispersion. After lowering extracellular [K(+)] in bradycardic hearts, no proarrhythmia occurred in amiodarone- or dronedarone-treated hearts whereas 11 of 17 sotalol-treated hearts showed early afterdepolarizations and subsequent polymorphic VT. Additional treatment with ranolazine reduced the number of VT episodes in sotalol-treated hearts and did not cause proarrhythmia in combination with amiodarone or dronedarone.
CONCLUSIONS: Application of ranolazine on top of class III drugs does not cause proarrhythmia despite a marked effect on ventricular repolarization. The effect of ranolazine on the repolarization reserve is associated with the lack of effect on early afterdepolarizations and dispersion of repolarization.
Copyright © 2012 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23044390     DOI: 10.1016/j.hrthm.2012.08.029

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  7 in total

1.  Severe proarrhythmic potential of risperidone compared to quetiapine in an experimental whole-heart model of proarrhythmia.

Authors:  Gerrit Frommeyer; Henning von der Ahe; Benedict Brücher; Dirk G Dechering; Philipp S Lange; Florian Reinke; Kristina Wasmer; Julia Köbe; Christian Pott; Gerold Mönnig; Lars Eckardt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-07-12       Impact factor: 3.000

Review 2.  Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms.

Authors:  Gerrit Frommeyer; Lars Eckardt
Journal:  Nat Rev Cardiol       Date:  2015-07-21       Impact factor: 32.419

3.  Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum.

Authors:  Jennifer L Smith; Allison R Reloj; Parvathi S Nataraj; Daniel C Bartos; Elizabeth A Schroder; Arthur J Moss; Seiko Ohno; Minoru Horie; Corey L Anderson; Craig T January; Brian P Delisle
Journal:  Am J Physiol Cell Physiol       Date:  2013-07-17       Impact factor: 4.249

4.  Effects of ranolazine on torsades de pointes tachycardias in a healthy isolated rabbit heart model.

Authors:  Samuel Sossalla; Nora Wallisch; Karl Toischer; Christian Sohns; Dirk Vollmann; Joachim Seegers; Lars Lüthje; Lars S Maier; Markus Zabel
Journal:  Cardiovasc Ther       Date:  2014-08       Impact factor: 3.023

5.  Current and emerging antiarrhythmic drug therapy for ventricular tachycardia.

Authors:  Eric S Williams; Mohan N Viswanathan
Journal:  Cardiol Ther       Date:  2013-02-20

Review 6.  Impact of ranolazine on ventricular arrhythmias - A systematic review.

Authors:  George Bazoukis; Gary Tse; Konstantinos P Letsas; Costas Thomopoulos; Katerina K Naka; Panagiotis Korantzopoulos; Xenophon Bazoukis; Paschalia Michelongona; Stamatis S Papadatos; Konstantinos Vlachos; Tong Liu; Michael Efremidis; Adrian Baranchuk; Stavros Stavrakis; Costas Tsioufis
Journal:  J Arrhythm       Date:  2018-01-12

7.  Safe electrophysiologic profile of dexmedetomidine in different experimental arrhythmia models.

Authors:  Christian Ellermann; Jonas Brandt; Julian Wolfes; Kevin Willy; Felix K Wegner; Patrick Leitz; Philipp S Lange; Florian Reinke; Lars Eckardt; Gerrit Frommeyer
Journal:  Sci Rep       Date:  2021-12-14       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.